Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Net Cash Flow (2019 - 2025)

Korro Bio (KRRO) has disclosed Net Cash Flow for 6 consecutive years, with -$9.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 66.17% year-over-year to -$9.5 million, compared with a TTM value of -$40.8 million through Sep 2025, down 338.79%, and an annual FY2024 reading of -$114.1 million, down 186.65% over the prior year.
  • Net Cash Flow was -$9.5 million for Q3 2025 at Korro Bio, up from -$30.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $121.8 million in Q4 2023 and bottomed at -$51.1 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$10.4 million, with a median of -$18.2 million recorded in 2023.
  • The sharpest move saw Net Cash Flow crashed 1202.96% in 2021, then surged 1897.37% in 2023.
  • Year by year, Net Cash Flow stood at -$32.4 million in 2021, then skyrocketed by 79.1% to -$6.8 million in 2022, then soared by 1897.37% to $121.8 million in 2023, then tumbled by 107.66% to -$9.3 million in 2024, then decreased by 1.36% to -$9.5 million in 2025.
  • Business Quant data shows Net Cash Flow for KRRO at -$9.5 million in Q3 2025, -$30.5 million in Q2 2025, and $8.5 million in Q1 2025.